GlassScriptPhysician profile
Jeff K Chang
NPI 1184862021
$16,719.60
in general payments reported to CMS, 2019-2025
23 companies · $3,844 in 2025
The $3,844 reported for 2025 was more than what 91% of Plastic Surgery providers received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.44 · 2020: $35.29 · 2021: $2,444 · 2022: $2,463 · 2023: $1,323 · 2024: $6,552 · 2025: $3,844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,796 · Travel and Lodging: $3,624 · Honoraria: $2,300 · Consulting Fee: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,796.23 |
| Travel and Lodging | $3,623.72 |
| Honoraria | $2,300.00 |
| Consulting Fee | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tela Bio, INC. | $5,485.70 | 2022-2025 | Ovitex 2s, Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Rti Surgical, INC | $3,782.20 | 2023-2025 | |
| Sientra, INC. | $1,971.23 | 2021-2022 | |
| Allergan, INC. | $1,712.91 | 2021 | |
| Axogen | $849.29 | 2022-2025 | Avance Nerve Graft, Axoguard Ha+ Nerve Protector, Axoguard Nerve Cap |
| Abbvie INC. | $683.86 | 2023-2025 | Revolve, Natrelle Saline-Filled Breast Implants |
| Aroa Biosurgery Incorporated | $375.43 | 2022-2024 | |
| Motiva USA, LLC | $311.49 | 2025 | |
| Integra Lifesciences Corporation | $308.38 | 2022-2023 | Integra, Omnigraft, Surgimend |
| Biocircuit Technologies INC | $278.77 | 2025 | Nerve Tape |
| Stryker Corporation | $186.18 | 2019-2021 | |
| Musculoskeletal Transplant Foundation INC. | $157.95 | 2024 | |
| Innovation Technologies INC | $149.33 | 2025 | Irrisept |
| Acera Surgical, INC. | $137.72 | 2022 | |
| Tempus Ai, INC | $73.83 | 2024 | Xt Cdx |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $48.03 | 2024 | Keytruda, Lynparza |
| Medical Microinstruments, INC. | $42.26 | 2024 | Symani Surgical Systems |
| Smith+Nephew, INC. | $36.35 | 2025 | Allevyn Life L 15.4x15.4 Ctn10 |
| Vioptix INC | $35.29 | 2020 | |
| Solventum Corporation | $28.25 | 2025 | V.A.C.Ulta |
| Daiichi Sankyo INC. | $27.37 | 2024 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $22.92 | 2023 | Enhertu |
| Kerecis Limited | $14.86 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeff Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.